Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.
Eron JJ Jr, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robertson MN, Sklar P, Nguyen BY; QDMRK Investigators. Eron JJ Jr, et al. Among authors: rizk ml. Lancet Infect Dis. 2011 Dec;11(12):907-15. doi: 10.1016/S1473-3099(11)70196-7. Epub 2011 Sep 18. Lancet Infect Dis. 2011. PMID: 21933752 Clinical Trial.
Raltegravir pharmacokinetics in neonates following maternal dosing.
Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1097 Study Team. Clarke DF, et al. Among authors: rizk ml. J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):310-5. doi: 10.1097/QAI.0000000000000316. J Acquir Immune Defic Syndr. 2014. PMID: 25162819 Free PMC article. Clinical Trial.
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.
Nachman S, Alvero C, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Rizk ML, Spector SA, Frenkel LM, Worrell C, Handelsman E, Wiznia A. Nachman S, et al. Among authors: rizk ml. J Pediatric Infect Dis Soc. 2015 Dec;4(4):e76-83. doi: 10.1093/jpids/piu146. Epub 2015 Feb 7. J Pediatric Infect Dis Soc. 2015. PMID: 26582887 Free PMC article. Clinical Trial.
53 results